Product Description
Mechanisms of Action: mAChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Canada | Cyprus | Czech | Denmark | Egypt | Hungary | India | Ireland | Israel | Italy | Jordan | Korea | Luxembourg | Malta | New Zealand | Pakistan | Peru | Saudi Arabia | Slovenia | Spain | Switzerland | United Arab Emirates | United Kingdom | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|